Korean Journal of Biological Psychiatry (생물정신의학)

The Korean Society of Biological Psychiatry (대한생물정신의학회)
권호 표지

Changes in the Metabolic Parameters and Positive and Negative Syndrome Scale (PANSS) Scores of Patients with Schizophrenia 8 Weeks after Switching to Paliperidone

Paliperidone으로 교체한 조현병 환자에서 8주 후 Metabolic Parameter와 Positive and Negative Syndrome Scale (PANSS) 점수의 변화

  • Jeong, Tae-Yeong (Department of Psychiatry, Sanggye Paik Hospital, Inje University College of Medicine) ;
  • Choi, Young-Min (Department of Psychiatry, Sanggye Paik Hospital, Inje University College of Medicine) ;
  • Kim, Bong-Seog (Department of Psychiatry, Sanggye Paik Hospital, Inje University College of Medicine) ;
  • Lee, Dong-Woo (Department of Psychiatry, Sanggye Paik Hospital, Inje University College of Medicine) ;
  • Gim, Min-Sook (Department of Psychiatry, Sanggye Paik Hospital, Inje University College of Medicine) ;
  • Park, Jun-Hyun (Department of Psychiatry, Sanggye Paik Hospital, Inje University College of Medicine)
  • 정태영 (인제대학교 의과대학 상계백병원 정신건강의학교실) ;
  • 최영민 (인제대학교 의과대학 상계백병원 정신건강의학교실) ;
  • 김봉석 (인제대학교 의과대학 상계백병원 정신건강의학교실) ;
  • 이동우 (인제대학교 의과대학 상계백병원 정신건강의학교실) ;
  • 김민숙 (인제대학교 의과대학 상계백병원 정신건강의학교실) ;
  • 박준현 (인제대학교 의과대학 상계백병원 정신건강의학교실)
  • Received : 2011.12.28
  • Accepted : 2012.03.26
  • Published : 2012.05.31
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives : The purpose of this study was to examine the changes in metabolic parameters and Positive and Negative Syndrome Scale (PANSS) scores of patients previously treated with atypical antipsychotic drugs other than paliperidone, after 8 weeks of treatment with paliperidone. Methods : Changes in body weight, body mass index, leptin, lipid levels, fasting glucose, and PANSS scores of patients who switched from other atypical antipsychotic drugs to paliperidone were measured after 8 weeks of treatment with paliperidone. We compared these results with those of patients who had not been treated with antipsychotic drugs for at least 2 weeks prior to treatment with paliperidone (antipsychotic drug-free patients). Results : The antipsychotic drug-free group (n = 9) did not show significant changes in metabolic parameters, but showed a significant improvement in total and subscale scores of PANSS. In the group that switched from other atypical antipsychotic drugs to paliperidone (n = 13), body weight, body mass index and fasting glucose level significantly increased, while total and subscale scores of PANSS significantly improved. Conclusions : Paliperidone treatment will benefit patients with schizophrenia who have been antipsychotic drug-free or who have had difficulty with other atypical antipsychotic drugs, with regard to their psychopathological state. However, if patients have been treated with other atypical antipsychotic drugs before switching to paliperidone, they could gain body weight or their fasting glucose level could increase over a short period because of a change in receptor number and sensitivity caused by the previously prescribed antipsychotic drugs, and hence, paliperidone should be prescribed with caution for these patients.

Keywords

References

  1. Son HI, Kwak KP, Sakong JK, Song CJ, Lee KH. The effect of atypical antipsychotics on weight. Dongguk Journal of Med 2004;11:135-144.
  2. Lee JB, Seo WS. Metabolic syndrome of second generation antipsychotic drugs. J Korean Soc Biol Ther Psychiatry 2007;13:138-146.
  3. Marino J, Caballero J. Paliperidone extended-release for the treatment of schizophrenia. Pharmacotherapy 2008;28:1283-1298. https://doi.org/10.1592/phco.28.10.1283
  4. Kane J, Canas F, Kramer M, Ford L, Gassmann-Mayer C, Lim P, et al. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res 2007;90:147-161. https://doi.org/10.1016/j.schres.2006.09.012
  5. Davidson M, Emsley R, Kramer M, Ford L, Pan G, Lim P, et al. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res 2007;93:117-130. https://doi.org/10.1016/j.schres.2007.03.003
  6. Marder SR, Kramer M, Ford L, Eerdekens E, Lim P, Eerdekens M, et al. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry 2007;62:1363-1370. https://doi.org/10.1016/j.biopsych.2007.01.017
  7. Cho HS, Kwon JS. Pharmacological Actions of Antipsychotics. In: Lee HS, editor. Clinical Neuropsychopharmacology. Seoul: ML Communications;2009. p.115-133.
  8. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276. https://doi.org/10.1093/schbul/13.2.261
  9. Marangell LB, Silver JM, Goff DC, Yudofsky SC. Psychopharmacology and Electroconvulsive Therapy. In: Hales RE, Yudofsky SC, editors. Textbook of clinical psychiatry. Vol II. Washington DC: American Psychiatric Publishing;2003. p.1047-1150.
  10. Canuso CM, Youssef EA, Bossie CA, Turkoz I, Schreiner A, Simpson GM. Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone. Int Clin Psychopharmacol 2008;23:209-215. https://doi.org/10.1097/YIC.0b013e3282fce651
  11. Samaha AN, Seeman P, Stewart J, Rajabi H, Kapur S. "Breakthrough" dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J Neurosci 2007;27:2979-2986. https://doi.org/10.1523/JNEUROSCI.5416-06.2007
  12. Choi YK, Moran-Gates T, Gardner MP, Tarazi FI. Effects of repeated risperidone exposure on serotonin receptor subtypes in developing rats. Eur Neuropsychopharmacol 2010;20:187-194. https://doi.org/10.1016/j.euroneuro.2009.09.002
  13. Silvestri S, Seeman MV, Negrete JC, Houle S, Shammi CM, Remington GJ, et al. Increased dopamine D2 receptor binding after longterm treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology (Berl) 2000;152:174-180. https://doi.org/10.1007/s002130000532
  14. Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry 2008;13:27-35. https://doi.org/10.1038/sj.mp.4002066
  15. Kim SF, Huang AS, Snowman AM, Teuscher C, Snyder SH. From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci U S A 2007;104:3456-3459. https://doi.org/10.1073/pnas.0611417104
  16. Masaki T, Yoshimatsu H, Chiba S, Watanabe T, Sakata T. Targeted disruption of histamine H1-receptor attenuates regulatory effects of leptin on feeding, adiposity, and UCP family in mice. Diabetes 2001;50:385-391. https://doi.org/10.2337/diabetes.50.2.385
  17. Minokoshi Y, Alquier T, Furukawa N, Kim YB, Lee A, Xue B, et al. AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature 2004;428:569-574. https://doi.org/10.1038/nature02440
  18. Wetterling T. Bodyweight gain with atypical antipsychotics. A comparative review. Drug Saf 2001;24:59-73. https://doi.org/10.2165/00002018-200124010-00005
  19. Reynolds GP, Zhang ZJ, Zhang XB. Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet 2002;359:2086-2087. https://doi.org/10.1016/S0140-6736(02)08913-4
  20. Templeman LA, Reynolds GP, Arranz B, San L. Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenet Genomics 2005;15:195-200. https://doi.org/10.1097/01213011-200504000-00002
  21. Arulmozhi DK, Dwyer DS, Bodhankar SL. Antipsychotic induced metabolic abnormalities: an interaction study with various PPAR modulators in mice. Life Sci 2006;79:1865-1872. https://doi.org/10.1016/j.lfs.2006.06.016
  22. Matsui-Sakata A, Ohtani H, Sawada Y. Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus. Drug Metab Pharmacokinet 2005;20:368-378. https://doi.org/10.2133/dmpk.20.368
  23. Silvestre JS, Prous J. Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes. Methods Find Exp Clin Pharmacol 2005;27:289-304. https://doi.org/10.1358/mf.2005.27.5.908643
  24. Mertens C. Long-term treatment of chronic schizophrenic patients with risperidone, in Risperidone: Major Progress in Antipsychotic Treatment. In: Kane JM, editor. Oxford: Oxford Clinical Communication; 1991. p.44-48.
  25. Lee MS, Kim YK, Kang BJ, Kim KS, Kim YH, Kim HC, et al. Efficacy and safety profile of risperidone in schizophrenia: long-term follow- up study. J Korean Neuropsychiatr Assoc 1999;38:116-127.
  26. Melkersson K, Dahl ML. Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs 2004;64:701-723. https://doi.org/10.2165/00003495-200464070-00003
  27. Graham KA, Perkins DO, Edwards LJ, Barrier RC Jr, Lieberman JA, Harp JB. Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis. Am J Psychiatry 2005;162:118-123. https://doi.org/10.1176/appi.ajp.162.1.118
  28. Kim YR, Kwon YJ, Park IJ, Jung HY, Woo KM, Cho MH. Body weight, body mass index, plasma leptin, insulin and fasting glucose level in schizophrenic patients receiving olanzapine. J Korean Neuropsychiatr Assoc 2001;40:1240-1246.
  29. McEvoy JP, Lieberman JA, Perkins DO, Hamer RM, Gu H, Lazarus A, et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 2007;164:1050-1060. https://doi.org/10.1176/appi.ajp.164.7.1050
  30. Turkoz I, Bossie CA, Dirks B, Canuso CM. Direct and indirect effects of paliperidone extended-release tablets on negative symptoms of schizophrenia. Neuropsychiatr Dis Treat 2008;4:949-958.
  31. Dirks B, Youssef E, Bossie C, Turkoz I, Canuso C. Effects of paliperidone ER in patients with schizophrenia previously treated with olanzapine. Proceeding of the International Congress on Schizophrenia Research;2007 March 28-April 1, Colorado, USA.
  32. de Leon J, Wynn G, Sandson NB. The pharmacokinetics of paliperidone versus risperidone. Psychosomatics 2010;51:80-88. https://doi.org/10.1016/S0033-3182(10)70664-2
  33. Vermeir M, Naessens I, Remmerie B, Mannens G, Hendrickx J, Sterkens P, et al. Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans. Drug Metab Dispos 2008;36:769-779. https://doi.org/10.1124/dmd.107.018275